Annovis Bio, Inc.

DB:07X Stock Report

Market Cap: €67.6m

Annovis Bio Management

Management criteria checks 2/4

Annovis Bio's CEO is Maria Maccecchini, appointed in May 2008, has a tenure of 16.67 years. total yearly compensation is $2.15M, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 7.96% of the company’s shares, worth €5.38M. The average tenure of the management team and the board of directors is 1 years and 9 years respectively.

Key information

Maria Maccecchini

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage31.1%
CEO tenure16.7yrs
CEO ownership8.0%
Management average tenureless than a year
Board average tenure9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Maria Maccecchini's remuneration changed compared to Annovis Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$668k

-US$56m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$3mUS$636k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$9mUS$510k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$420k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$120kUS$120k

-US$991k

Sep 30 2019n/an/a

-US$958k

Jun 30 2019n/an/a

-US$841k

Mar 31 2019n/an/a

-US$715k

Dec 31 2018US$155kUS$120k

-US$714k

Compensation vs Market: Maria's total compensation ($USD2.15M) is above average for companies of similar size in the German market ($USD464.61K).

Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.

CEO

Maria Maccecchini (73 yo)

16.7yrs

Tenure

US$2,145,852

Compensation

Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...

Leadership Team

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder16.7yrsUS$2.15m7.96%
€ 5.4m
Mark White
Chief Business Officer & Directorless than a yearUS$135.43k0.44%
€ 299.5k
William Fricker
Chief Financial Officerless than a yearno datano data
Cheng Fang
Senior Vice President of Research & Development3yrsno datano data
Eve Damiano
Senior Vice President of Regulatory Operations3yrsno datano data
Melissa Gaines
Senior Vice President of Clinical Operations1.4yrsno datano data
Blake Jensen
Head of Qualityless than a yearno datano data
Hilda Maibach
Senior Vice President of Statisticsless than a yearno datano data

1.0yrs

Average Tenure

68yo

Average Age

Experienced Management: 07X's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder16.7yrsUS$2.15m7.96%
€ 5.4m
Mark White
Chief Business Officer & Director9yrsUS$135.43k0.44%
€ 299.5k
Michael M. Hoffman
Independent Chairman of the Board11yrsUS$153.92k11.88%
€ 8.0m
Jeffrey Cummings
Chief Medical Advisor & Member of Scientific Advisory Boardno datano datano data
Gregory Petsko
Member of Scientific Advisory Board8yrsno datano data
Reid McCarthy
Independent Director3.8yrsUS$143.92k0.053%
€ 35.8k
Sidney Strickland
Chairman of Scientific Advisory Board8yrsno datano data
Claudine Bruck
Independent Director10yrsUS$135.43k0.048%
€ 32.2k

9.0yrs

Average Tenure

71.5yo

Average Age

Experienced Board: 07X's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 16:16
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Annovis Bio, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tyler BussianBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.